Journal article

Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials

Wei Zheng, Xiao-Min Zhu, Qing-E Zhang, Dong-Bin Cai, Xin-Hu Yang, Yan-Ling Zhou, Gabor S Ungvari, Chee H Ng, Shu-Hua He, Xiao-Jiang Peng, Yu-Ping Ning, Yu-Tao Xiang

Schizophrenia Research | ELSEVIER | Published : 2019

Abstract

OBJECTIVE: As a non-competitive N-methyl-d-aspartate receptor antagonist, memantine has been used to treat major mental disorders including schizophrenia, bipolar disorder, and major depressive disorder (MDD). This meta-analysis systematically investigated the effectiveness and tolerability of adjunctive memantine for patients with schizophrenia, bipolar disorder, and MDD. METHODS: Only randomized controlled trials (RCTs) were identified and included in the study. Data of the three disorders were separately synthesized using the RevMan 5.3 software. RESULTS: Fifteen RCTs (n = 988) examining memantine (5-20 mg/day) as an adjunct treatment for schizophrenia (9 trials with 512 patients), bipola..

View full abstract

University of Melbourne Researchers

Grants

Awarded by University of Macau


Awarded by Affiliated Brain Hospital of Guangzhou Medical University


Awarded by Science and Technology Department, Guangdong Province major science and technology


Awarded by Natural Science Foundation of Jiangsu Province


Funding Acknowledgements

The study was supported by the University of Macau (SRG2014-00019-FHS; MYRG2015-00230-FHS; MYRG2016-00005-FHS), the Affiliated Brain Hospital of Guangzhou Medical University (2016YFC0906302; 2014Y2-00105; 2015BAI13B02), Science and Technology Department, Guangdong Province major science and technology (2016B010108003), and the Natural Science Foundation of Jiangsu Province (Grants No BK20180213). The University of Macau and the Affiliated Brain Hospital of Guangzhou Medical University had no role in the study design, generating or interpreting the results and publication of the study.